Drugs / CYL-02
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01274455 | Dec 2010 → Mar 2013 | pancreatic adenocarcinoma | University Hospital, Toulouse | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02806687 | Jan 2017 → Jun 2022 | pancreatic adenocarcinoma | University Hospital, Toulouse | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CYL-02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02806687 ↗ |
| Modality | Other / unclassified | “plasmid DNA pre-complexed to PEI (polyethylenimine - non-viral vector)” NCT01274455 ↗ |
| Route | Other | “Intratumor injections of the gene therapy product (CYL-02) will be performed by transgastric or transduodenal route under endoscopic ultrasound guidance.” NCT01274455 ↗ |